Body Shortcuts
R&D JW, leading global new drug development

Research Pipeline

  • Discovery
  • Lead optimization
  • Pre-clinical
  • Phase Ⅰ
  • Phase II
  • Phase III
  • Registration
Category Code name Development phase Being in adjustment
  Liver cancer (for surgical patients)
    Liver cancer (targeted at carotid chemistry and color transmutation patients)


Summary of Phase II clinical trial

  1. CreaVax-HCC was well tolerated to firstly diagnosed early HCC patients.
  2. CreaVax-HCC showed significant inhibition of tumor recurrence with curative hepatic resection suggesting increase of recurrence free survival in two years

Summary of Phase III clinical trial

  1. Study design : A Multi-centered, randomized, double-blind, placebo-controlled Phase III study on the efficacy and safety of CreaVax-HCC in patients with hepatocellular carcinoma for comparing after curative hepatic resection
  2. Target patients : Early HCC patients after curative hepatic resection with CR confirmation (n=166)
  3. Current state : Completion of Enrollment